Jane Street
ADMA icon

Jane Street’s ADMA Biologics ADMA Stock Holding History

Jane Street’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54M Sell
662,082
-2,389,861
-78% -$21.8M ﹤0.01% 3563
2026
Q1 		$27.5M Buy
3,051,943
+2,592,519
+564% +$40.9M ﹤0.01% 1510
2025
Q4 		$8.38M Sell
459,424
-272,907
-37% -$4.6M ﹤0.01% 2540
2025
Q3 		$10.7M Buy
+732,331
New +$12.6M ﹤0.01% 2327
2025
Q1 		– Sell
-59,989
Closed -$1.04M – 9303
2024
Q4 		$1.03M Sell
59,989
-375,137
-86% -$7.06M ﹤0.01% 5338
2024
Q3 		$8.7M Buy
435,126
+535
+0.1% +$8.32K ﹤0.01% 2075
2024
Q2 		$4.86M Buy
434,591
+338,961
+354% +$2.84M ﹤0.01% 2998
2024
Q1 		$631K Sell
95,630
-58,924
-38% -$322K ﹤0.01% 6245
2023
Q4 		$699K Buy
154,554
+69,118
+81% +$256K ﹤0.01% 6197
2023
Q3 		$306K Sell
85,436
-326,182
-79% -$1.26M ﹤0.01% 7030
2023
Q2 		$1.52M Buy
411,618
+396,943
+2,705% +$1.47M ﹤0.01% 4579
2023
Q1 		$48.6K Sell
14,675
-161,185
-92% -$557K ﹤0.01% 8461
2022
Q4 		$682K Buy
175,860
+128,022
+268% +$395K ﹤0.01% 5616
2022
Q3 		$116K Buy
47,838
+33,205
+227% +$79.7K ﹤0.01% 8568
2022
Q2 		$29K Sell
14,633
-609,733
-98% -$1.2M ﹤0.01% 9066
2022
Q1 		$1.14M Buy
624,366
+548,579
+724% +$856K ﹤0.01% 5855
2021
Q4 		$107K Buy
75,787
+42,281
+126% +$55.6K ﹤0.01% 9211
2021
Q3 		$38K Sell
33,506
-21,971
-40% -$30.8K ﹤0.01% 9626
2021
Q2 		$89K Buy
55,477
+32,865
+145% +$57.8K ﹤0.01% 9315
2021
Q1 		$40K Buy
+22,612
New +$51.8K ﹤0.01% 8878
2020
Q4 		– Sell
-20,056
Closed -$48K – 7407
2020
Q3 		$48K Buy
+20,056
New +$55K ﹤0.01% 6921
2020
Q2 		– Sell
-35,333
Closed -$102K – 7008
2020
Q1 		$102K Sell
35,333
-128,158
-78% -$443K ﹤0.01% 4930
2019
Q4 		$654K Buy
163,491
+29,196
+22% +$127K ﹤0.01% 3351
2019
Q3 		$598K Buy
134,295
+75,921
+130% +$317K ﹤0.01% 3319
2019
Q2 		$226K Buy
58,374
+11,711
+25% +$51.7K ﹤0.01% 4563
2019
Q1 		$177K Buy
+46,663
New +$165K ﹤0.01% 4681

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jane Street's ADMA Position: Q2 2026 in Review

Jane Street reduced its ADMA Biologics (ADMA) stake by 78% in Q2 2026, selling an estimated $21.8M and leaving 662,082 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

Jane Street first reported a position in ADMA in Q1 2019 and has held it in 26 quarters since. The position peaked at $27.5M in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Jane Street held 662,082 shares of ADMA Biologics worth $5.54M as of Q2 2026.
  • Jane Street sold 2,389,861 ADMA Biologics shares in Q2 2026, an estimated $21.8M.
  • ADMA Biologics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3563 holding.
  • Jane Street first reported a position in ADMA Biologics in Q1 2019 and has held it in 26 quarters since.
  • Jane Street's ADMA Biologics position peaked at $27.5M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.